Trial Profile
Efficacy of anti-PD1 drugs nivolumab or pembrolizumab in pateints with metastatic uveal melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 21 Jul 2016 New trial record
- 07 Jun 2016 Results (n=21) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.